Literature DB >> 3312021

Cefuroxime axetil in acute purulent exacerbations of chronic bronchitis.

B I Davies1, F P Maesen, J P Teengs.   

Abstract

51 hospitalised patients with acute purulent exacerbations of chronic bronchitis were treated for ten days with two daily 1 g doses of the orally absorbed pro-drug cefuroxime axetil. However, some patients were still infected with Haemophilus influenzae or Branhamella catarrhalis at follow-up, and sputum purulence remained. Clinical results were "excellent" or "good" in 60% of the evaluable patients one week after the end of the treatment. Mean peak serum concentrations averaged 12.8 mg/l with mean peak sputum concentrations of 1.8 mg/l. The MIC90 value for H. influenzae was 4 mg/l. Three patients discontinued cefuroxime because of unwanted gastrointestinal drug effects, and three because of insufficient improvement. These results do not suggest that this compound is indicated for such patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312021     DOI: 10.1007/BF01644126

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Studies on the treatment with antibacterial drugs of acute and chronic mucopurulent bronchitis caused by Hemophilus influenzae.

Authors:  J MULDER; W R O GOSLINGS; M C VAN DER PLAS; P L CARDOZO
Journal:  Acta Med Scand       Date:  1952-05-10

2.  The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid.

Authors:  R Wise; S A Bennett; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

3.  Cefoperazone in acute exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; J Brouwers
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

4.  Sputum and blood concentrations of cefuroxime in lower respiratory tract infection.

Authors:  C W Havard; R P Bax; T C Samanta; R M Pearson; W Brumfitt; J M Hamilton-Miller; C H Dash
Journal:  Thorax       Date:  1980-05       Impact factor: 9.139

5.  Twice daily dosage of bacampicillin in chronic bronchitis. A double-blind study.

Authors:  B I Davies; F P Maesen; P J Brombacher; J Sjövall
Journal:  Scand J Respir Dis       Date:  1978-10

6.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

7.  Oral cefuroxime axetil: clinical pharmacology and comparative dose studies in urinary tract infection.

Authors:  D H Adams; M J Wood; I D Farrell; C Fox; A P Ball
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

8.  A comparison of oral cefuroxime axetil and oral amoxycillin in lower respiratory tract infections.

Authors:  T J Cooper; E Ladusans; P E Williams; V Polychronopoulos; H Gaya; R M Rudd
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

9.  Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.

Authors:  S M Harding; P E Williams; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

10.  The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food.

Authors:  P E Williams; S M Harding
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

View more
  4 in total

1.  Concentrations of cefixime in bronchial mucosa and sputum.

Authors:  F P Maesen; R Costongs; B I Davies
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

2.  Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia.

Authors:  Almos Klekner; Kinga Bagyi; Laszlo Bognar; Attila Gaspar; Melinda Andrasi; Judit Szabo
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 3.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

Review 4.  Epidemiology and treatment of chronic bronchitis and its exacerbations.

Authors:  P Ball
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.